Study of Patidegib Topical Gel, 2%, for the Reduction of Disease Burden of Persistently Developing Basal Cell Carcinomas (BCCs) in Subjects With Basal Cell Nevus Syndrome (Gorlin Syndrome)
Clinical trial NCT03703310 · COMPLETED
Trial details
- NCT number
- NCT03703310
- Sponsor
- Sol-Gel Technologies, Ltd.
- Status
- COMPLETED
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2019-02-19
- Primary completion
- 2020-12-28
- Enrollment
- 174
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.